Ranbaxy Launches AG Version Of Caduet As CEO Likens Lipitor Deal With Teva To An Insurance Policy
This article was originally published in PharmAsia News
Both Ranbaxy and Mylan appear to have agreed to sell all doses of Caduet under separate authorized generic deals with Pfizer.
You may also be interested in...
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.